Publication Name	World Journal of Gastroenterology
Manuscript ID	70305
Country	Japan

Received	2021-07-29 09:22
Peer-Review Started	2021-07-29 09:28
To Make the First Decision
Return for Revision	2021-11-07 21:02
Revised	2021-11-18 09:27
Second Decision	2021-12-09 03:41
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-12-10 02:42
Articles in Press	2021-12-10 02:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-12-17 04:01
Publish the Manuscript Online	2021-12-24 09:48

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
Manuscript Source	Invited Manuscript
All Author List	Ken Sato, Yuichi Yamazaki and Toshio Uraoka
ORCID	Author(s) ORCID Number Ken Sato http://orcid.org/0000-0002-3202-7983 Yuichi Yamazaki http://orcid.org/0000-0002-8633-2983 Toshio Uraoka http://orcid.org/0000-0002-4425-4331
Funding Agency and Grant Number
Corresponding Author	Ken Sato, MD, PhD, Associate Professor, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan. satoken@gunma-u.ac.jp
Key Words	Coronavirus disease 2019; Drug-induced liver injury; Cytochrome P450; Drug-drug interaction; Drug-disease interaction; Cytokine
Core Tip	To cope with dysregulation of liver function in coronavirus disease 2019 (COVID-19), drug-induced liver injury (DILI) due to investigational treatments/drugs or drug-drug or drug-disease interactions should be considered. We described useful information associated with clinical practice. We discussed the potential hepatotoxicity of dexamethasone or remdesivir as representative investigational treatments/drugs for COVID-19. These drugs are predicted to be used for a certain time in monotherapy or combination therapy. We also reported glycyrrhizic acid and ursodeoxycholic acid as therapeutic candidates for the control of DILI due to investigational treatments/drugs, as well as COVID-19.
Publish Date	2021-12-24 09:48
Citation	Sato K, Yamazaki Y, Uraoka T. Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19. World J Gastroenterol 2021; 27(48): 8370-8373
URL	https://www.wjgnet.com/1007-9327/full/v27/i48/8370.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i48.8370

Full Article (PDF)	WJG-27-8370.pdf
Full Article (Word)	WJG-27-8370.docx
Manuscript File	70305_Auto_Edited.docx
Answering Reviewers	70305-Answering reviewers.pdf
Audio Core Tip	70305-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	70305-Conflict-of-interest statement.pdf
Copyright License Agreement	70305-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	70305-Language certificate.pdf
Peer-review Report	70305-Peer-review(s).pdf
Scientific Misconduct Check	70305-Bing-Wu YXJ-2.png
Scientific Editor Work List	70305-Scientific editor work list.pdf